We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

496 hedge funds and large institutions have $26.7B invested in Alnylam Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 118 funds opening new positions, 170 increasing their positions, 151 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

203% more first-time investments, than exits

New positions opened: 118 | Existing positions closed: 39

83% more funds holding in top 10

Funds holding in top 10: 6 → 11 (+5)

62% more capital invested

Capital invested by funds: $16.5B → $26.7B (+$10.2B)

18% more funds holding

Funds holding: 421 → 496 (+75)

17.7% more ownership

Funds ownership: 93.9% → 111.6% (+18%)

13% more repeat investments, than reductions

Existing positions increased: 170 | Existing positions reduced: 151

11% more call options, than puts

Call options by funds: $298M | Put options by funds: $270M

Holders
496
Holders Change
+75
Holders Change %
+17.81%
% of All Funds
8.54%
Holding in Top 10
11
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+83.33%
% of All Funds
0.19%
New
118
Increased
170
Reduced
151
Closed
39
Calls
$298M
Puts
$270M
Net Calls
+$28.8M
Net Calls Change
-$110M

Top Buyers

1
N
Nuveen
North Carolina
+$3.11B
2
Capital World Investors
Capital World Investors
California
+$698M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$133M
4
Holocene Advisors
Holocene Advisors
New York
+$123M
5
Invesco
Invesco
Georgia
+$109M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$625M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$262M
3
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$142M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$114M
5
AG
Artal Group
Luxembourg
-$87.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
IHAM
101
Integral Health Asset Management
New York
$14M +$4.39M +23,034 +49%
VanEck Associates
102
VanEck Associates
New York
$14M -$7.54M -39,546 -36%
DCM
103
Driehaus Capital Management
Illinois
$13.6M +$2.25M +11,812 +21%
CI
104
Capital International
California
$13.6M +$4.2M +22,023 +48%
Royal Bank of Canada
105
Royal Bank of Canada
Ontario, Canada
$13.2M -$2.88M -15,087 -19%
BNP Paribas Asset Management
106
BNP Paribas Asset Management
France
$13.1M +$2.27M +11,893 +22%
Wells Fargo
107
Wells Fargo
California
$12.8M -$1.72M -8,996 -12%
Two Sigma Advisers
108
Two Sigma Advisers
New York
$12.8M +$9.8M +51,400 +415%
Ohio Public Employees Retirement System (OPERS)
109
Ohio Public Employees Retirement System (OPERS)
Ohio
$12.3M +$46.5K +244 +0.4%
Lazard Asset Management
110
Lazard Asset Management
New York
$12M +$11.3M +59,349 +8,130%
TRSOTSOK
111
Teachers Retirement System of the State of Kentucky
Kentucky
$11.9M +$11.3M +59,457 New
Victory Capital Management
112
Victory Capital Management
Texas
$11.8M +$1.49M +7,822 +15%
Nomura Asset Management
113
Nomura Asset Management
Japan
$11.8M -$415K -2,176 -4%
Korea Investment Corp
114
Korea Investment Corp
South Korea
$11.4M +$366K +1,921 +3%
Asset Management One
115
Asset Management One
Japan
$9.78M -$497K -2,607 -5%
AAF
116
Andra AP-fonden
Sweden
$9.73M +$1.24M +6,500 +15%
NIP
117
Nicholas Investment Partners
California
$9.67M +$233K +1,222 +3%
Balyasny Asset Management
118
Balyasny Asset Management
Illinois
$9.56M -$3M -15,732 -25%
JG
119
Jefferies Group
New York
$9.35M +$5.69M +29,831 +177%
Zurich Cantonal Bank
120
Zurich Cantonal Bank
Switzerland
$9.26M +$39.3K +206 +0.4%
UBS Group
121
UBS Group
Switzerland
$9.15M +$3.93M +20,629 +82%
PHK
122
Point72 Hong Kong
Hong Kong
$8.92M +$8.5M +44,547 New
CIS
123
Capital International Sarl
California
$8.87M +$2.57M +13,456 +44%
Macquarie Group
124
Macquarie Group
Australia
$8.86M +$258K +1,352 +3%
TI
125
Trexquant Investment
Connecticut
$8.63M +$8.22M +43,112 New
3 4
5
6 7

ALNY Hedge Fund Activity: Q3 2022 in Review

496 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2022, worth a combined $26.7B — up 62% from $16.5B a quarter earlier.

Buyers outnumbered sellers: 118 funds opened new ALNY positions and 39 closed out — a net gain of 79 holders — while 170 added to existing stakes and 151 trimmed.

The largest buyer was Nuveen, adding an estimated $3.11B. The largest seller was T. Rowe Price Associates, cutting an estimated $625M.

  • 496 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2022, up from 421 in Q2 2022.
  • Funds reported $26.7B of Alnylam Pharmaceuticals stock for Q3 2022, up 62% quarter-over-quarter.
  • 118 funds opened new Alnylam Pharmaceuticals positions in Q3 2022 and 39 closed out, a net change of +79 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2022 was Nuveen, an estimated $3.11B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2022 was T. Rowe Price Associates, an estimated $625M sold.

Based on aggregated 13F filings for Q3 2022.